WuXi PharmaTech (pronounced woo-shee pharma-tek) is a leading global contract R&D services provider serving the pharmaceutical, biotech, and medical device industries. The company is headquartered in Shanghai and has operations in both China and the United States. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process. Our services are designed to help our global partners shorten the time and lower the cost of R&D. The parent company is known as WuXi PharmaTech, and its operating divisions are known as WuXi AppTec (pronounced woo-shee app-tek)... More >>
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China
CAMBRIDGE, Mass. and SHANGHAI, Oct. 22, 2014 /PRNewswire/-- Foundation Medicine, Inc. (NASDAQ:FMI) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX) today announced a collaboration to offer Foundation Medicine's comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.
Under the terms of the collaboration, Foundation Medicine will license and ...
SHANGHAI, Oct. 21, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the third quarter of 2014 after the New York Stock Exchange closes on Wednesday, November 12, 2014 (which will be Thursday morning, November 13, 2014 Shanghai time)....
SHANGHAI, Oct. 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (WuXi) (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, a...
SHANGHAI, Sept. 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William Robert Keller as an independent director on the Board of Directors. He will serve on the Strategy Committee.
Mr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2003, and he served ...
Calendar Icon Legend:
Corporate Conference Call
Earnings Conference Call
Mergers & Acquisition Announcement
52 Week High
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever WuXi PharmaTech (Cayman) Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.